J Korean Diabetes.  2020 Mar;21(1):36-40. 10.4093/jkd.2020.21.1.36.

Effective Use of Insulin Pump in Patients with Type 1 Diabetes

• Gu M

• KMID: 2506772
• DOI: http://doi.org/10.4093/jkd.2020.21.1.36

Abstract

In young patients with type 1 diabetes, insulin pump therapy lowers the risk of severe hypoglycemia and diabetic ketoacidosis compared to insulin injection therapy. It also increases lifestyle flexibility and improves glucose control. However, appropriate use of insulin pumps requires structured education programs to improve patient self-care. In addition, feedback and ongoing attention from diabetes educators are needed. For this purpose, a systematic education program for medical staff related to insulin pump treatment should be pursued in Korea.

Keyword

Diabetes mellitus; type 1; Education; Insulin pump

Reference

1. Heinemann L, Fleming GA, Petrie JR, Holl RW, Bergenstal RM, Peters AL. Insulin pump risks and benefits: a clinical appraisal of pump safety standards, adverse event reporting, and research needs: a joint statement of the European Association for the Study of Diabetes and the American Diabetes Association Diabetes Technology Working Group. Diabetes Care. 2015; 38:716–22.

2. Grunberger G, Abelseth JM, Bailey TS, Bode BW, Handelsman Y, Hellman R, Jovanovič L, Lane WS, Raskin P, Tamborlane WV, Rothermel C. Consensus Statement by the American Association of Clinical Endocrinologists/American College of Endocrinology insulin pump management task force. Endocr Pract. 2014; 20:463–89.

3. Karges B, Schwandt A, Heidtmann B, Kordonouri O, Binder E, Schierloh U, Boettcher C, Kapellen T, Rosenbauer J, Holl RW. Association of insulin pump therapy vs insulin injection therapy with severe hypoglycemia, ketoacidosis, and glycemic control among children, adolescents, and young adults with type 1 diabetes. JAMA. 2017; 318:1358–66.

4. Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB, Dailey G, Davis SN, Joyce C, Peoples T, Perkins BA, Welsh JB, Willi SM, Wood MA; STAR 3 Study Group. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med. 2010; 363:311–20.

5. Zimmerman C, Albanese-O’Neill A, Haller MJ. Advances in type 1 diabetes technology over the last decade. Eur Endocrinol. 2019; 15:70–6.

6. Barnard KD, Speight J, Skinner TC. Quality of life and impact of continuous subcutaneous insulin infusion for children and their parents. Pract Diabetes Int. 2008; 25:278–83.

7. Korean Diabetes Association. Treatment guideline for diabetes. 4th ed. Seoul: gold’ Planning and Development;2019. p. 52–6.

8. Ehrmann D, Kulzer B, Schipfer M, Lippmann-Grob B, Haak T, Hermanns N. Efficacy of an education program for people with diabetes and insulin pump treatment (INPUT): results from a randomized controlled trial. Diabetes Care. 2018; 41:2453–62.

9. Pickup JC. Insulin-pump therapy for type 1 diabetes mellitus. N Engl J Med. 2012; 366:1616–24.

10. Evert AB, Bode BW, Buckingham BA, Nardacci E, Verderese CA, Wolff-McDonagh P, Walsh J, Hirsch IB. Improving patient experience with insulin infusion sets: practical guidelines and future directions. Diabetes Educ. 2016; 42:470–84.

11. American Diabetes Association. Standards of medical care in diabetes-2017-glycemic targets. Diabetes Care. 2017; 40(Suppl 1):S48–56.

12. Walsh J, Roberts R, Bailey T. Guidelines for insulin dosing in continuous subcutaneous insulin infusion using new formulas from a retrospective study of individuals with optimal glucose levels. J Diabetes Sci Technol. 2010; 4:1174–81.

13. Handelsman Y, Mechanick JI, Blonde L, Grunberger G, Bloomgarden ZT, Bray GA, Dagogo-Jack S, Davidson JA, Einhorn D, Ganda O, Garber AJ, Hirsch IB, Horton ES, Ismail-Beigi F, Jellinger PS, Jones KL, Jovanovič L, Lebovitz H, Levy P, Moghissi ES, Orzeck EA, Vinik AI, Wyne KL. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan. Endocr Pract. 2011; 17(Suppl 2):1–53.

14. American Association of Diabetes Educators. Practice paper – Continuous Subcutaneous Insulin Infusion (CSII) without and with sensor integration. Available from https://www.diabeteseducator.org/practice/practicetools/diabetes-management-tools/ipt-resources.

15. Bolderman K. “Pump Start-Up” in putting your patients on the pump. Alexandria, Va: American Diabetes Association;2013.

16. Mameli C, Scaramuzza AE, Ho J, Cardona-Hernandez R, Suarez-Ortega L, Zuccotti GV. A 7-year follow-up retrospective, international, multicenter study of insulin pump therapy in children and adolescents with type 1 diabetes. Acta Diabetol. 2014; 51:205–10.

17. O’Connell MA, Donath S, Cameron FJ. Poor adherence to integral daily tasks limits the efficacy of CSII in youth. Pediatr Diabetes. 2011; 12:556–9.

18. Evert A. Insulin pump therapy troubleshooting for optimal performance. Empower. 2015; 7:23–4.

19. Guilhem I, Leguerrier AM, Lecordier F, Poirier JY, Maugendre D. Technical risks with subcutaneous insulin infusion. Diabetes Metab. 2006; 32:279–84.